LECTURES
The analysis of currently available definitions of the term «radiotherapeutic interval» (RTI) has showed that they contain significant uncertainties and do not take into account the dose fractionation regimen. The aim of the study was to analyze the current approaches to the definition of the term «radiotherapeutic interval» and to propose a new definition excluding uncertainties and taking into account the dose fractionation regi- men. materials and methods. A new approach to the assessment of radiotherapeutic interval was applied to superficial tumors treated with X-rays and fast electron beams. The features of dose distributions characteristic of X-ray and monoenergetic fast electron beams generated in radiotherapy of superficial malignant tumors 10 SIBERIAN JOURNAL OF ONCOLOGY. 2016. VOL. 15, № 3. Р. 5-11 в.а. лисин сПОсОб ОЦенКИ раДИОтераПевтИчесКОГО Интервала were studied. The relationship between radiotherapeutic interval and tumor size for Х-ray and monoenergetic fast electron beam radiotherapy was calculated. The algorithm of calculation was consistent with the new definition of the concept of «radiotherapeutic interval». Results. A new approach to the definition of «radio- therapeutic interval», which avoids the previous definition’s inherent uncertainties and contradictions and takes into account the dose fractionation regimen, has been proposed.

EPIDEMIOGICAL STUDIES
CLINICAL STUDIES
The present study was undertaken to determine the relationship between tumor response to neoadjuvant chemotherapy including capecitabine and long-term treatment outcomes in patients with operable breast cancer. material and methods. The study included 139 patients with stage T2-3N0-2M0 breast cancer, who received 2-4 courses of neoadjuvant chemotherapy with the FAC and САХ regimens. Immediate response was assessed using the RECIST criteria. Long-term treatment outcomes and metastasis-free survival rates were evaluated using the Kaplan-Meier method. Results. By assessing the relationship between long-term treatment outcomes and the immediate response to adjuvant chemotherapy with capecitabine, we identified the group of patients with tumor regression ≥ 80%, who had the 7-year metastasis-free survival rates similar to those observed in patients with pathologic complete response. Such factors as the primary tumor size, regional tumor spread, receptor status of tumor tissue and the number of chemotherapy courses were found to have no impact on the frequency of hematogenous metastasis. Conclusion. The results obtained indicate that ≥ 80% tumor regression after neoadjuvanch chemotherapy including capecitabine can be considered as a predictive parameter for assessing metastasis-free survival in patients with operable breast cancer.

Introduction. The introduction of modern technologies of conformal external beam radiotherapy (EBRT) into clinical practice for the treatment of prostate cancer requires proper quality assurance measures as well as a careful analysis of both the efficacy and toxicity data of treatments. The purpose of this study was to inves- tigate tolerance and the immediate efficacy of conformal dose-escalated EBRT during hormono-radiotherapy for prostate cancer. material and methods. The study involved 156 prostate cancer patients treated with EBRT. Among them, 30 patients received a total dose of 70 Gy, and in 126 patients the total dose was esca- lated to 72-76 Gy (median total dose - 74.0 Gy). Fifty-nine patients received intensity modulated radiation therapy. Results. The prescribed course of treatment was completed in all the patients with prostate cancer. Acute radiation-induced bladder reactions (RTOG) were observed in 50 (32.1 %) patients, of whom 48 (30.8 %) experienced grade I reactions, and 2 (1.3 %) experienced grade II reactions. Eighteen (11.5 %) patients had radiation-induced rectum reactions, not above grade I. The development of grade II dysuric phenomena necessitated treatment interruption only in two patients. Of 9 (5.8 %) patients who had late bladder complica- tions (RTOG/EORTC), 8 (5.1 %) patients developed grade I complications, and one (0.6 %) patient developed grade II complications. Of 11 (7.1 %) patients who had rectum complications, 8 (5.1 %) patients developed grade I complications, and 3 (1.9 %) patients developed grade II complications. No patients experienced the increase in toxicity of treatment during dose escalation up to a total dose exceeding 70 Gy. During the follow-up period, only one patient developed recurrent disease. Conclusion. The results of our study suggest acceptable levels of toxicity following a continuous course of dose-escalated EBRT given in conjunction with hormono-radiotherapy to prostate cancer patients. Further studies are needed to investigate the impact of dose escalation on long-term outcomes as well as the rate and grade of late complications.

LABORATORY AND EXPERIMENTAL STUDIES
ONCOLOGY PRACTICE
The results of the combined modality treatment including neutron therapy for patients with resistant malignant tumors were presented. Efficacy of neutron therapy was assessed using disease-free and 5-year survival rates. Neutron therapy used alone or as a combination therapy was shown to be more effective than photon therapy. A comprehensive program for the prevention and treatment of acute radiation-induced damages was devised.

The treatment outcomes of unresectable laryngeal cancer have been presented. The techniques of radiation therapy (RT) alone and concurrent chemoradiotherapy (CRT), as well as the effect of changes in the fractionation regimens on the treatment outcome have been analyzed. No differences in overall survival (OS) and locoregional control (LC) between the RT and CRT techniques were found (p<0.8). There is a trend toward improvement in OS (p<0.1) and LC (p<0.05) in laryngeal cancer patients treated with hyperftactionated radiation therapy.

REVIEWS
Laryngeal and hypopharyngeal cancer takes the leading position among malignant head and neck tumors, representing one of the most important and socially significant problems in modern oncology. Approaches to the treatment of locally advanced laryngeal or hypopharyngeal cancer have changed significantly in the recent years, due to new anticancer drugs and the widespread use of the best types of chemotherapy combined with surgery and radiotherapy.

CASE REPORTS
ISSN 2312-3168 (Online)